CBD reduced heart damage, inflammation, and cell death in diabetic mice
Cannabidiol (CBD) attenuated cardiac dysfunction, fibrosis, oxidative stress, inflammation, and cell death in a mouse model of diabetic cardiomyopathy and in human heart cells exposed to high glucose.
Quick Facts
What This Study Found
Researchers tested CBD in a mouse model of type I diabetic cardiomyopathy and in human heart cells exposed to high glucose conditions.
In diabetic mice, the heart showed declining function, increased oxidative stress, elevated inflammatory markers (NF-kB activation, TNF-alpha, adhesion molecules), fibrosis markers, and enhanced cell death. CBD treatment significantly attenuated all of these pathological processes.
In human cardiomyocytes (heart cells) exposed to high glucose, CBD reduced reactive oxygen species generation, NF-kB activation, and cell death.
The authors noted that CBD's established safety profile in humans made it a strong candidate for further investigation in diabetic cardiovascular complications.
Key Numbers
CBD attenuated: NF-kB and MAPK activation, adhesion molecule expression (ICAM-1, VCAM-1), TNF-alpha, fibrosis markers (TGF-beta, CTGF, fibronectin, collagen-1, MMP-2/9), and caspase 3/7 activity. Results were significant across multiple markers.
How They Did This
Preclinical study using a type I diabetic mouse model. Left ventricular function measured by pressure-volume system. Oxidative stress, cell death, and fibrosis assessed by molecular biology techniques, electron spin resonance spectroscopy, and flow cytometry. Also tested in primary human cardiomyocytes exposed to high glucose.
Why This Research Matters
Diabetic cardiomyopathy is a serious complication of diabetes with limited treatment options. The finding that CBD addressed multiple pathological pathways simultaneously (inflammation, oxidative stress, fibrosis, cell death) was notable.
The Bigger Picture
This study positioned CBD as a potential multi-target therapeutic for diabetic heart disease, addressing inflammation, oxidative damage, and tissue scarring through a single compound with a known safety profile.
What This Study Doesn't Tell Us
Animal model (type I diabetes in mice) may not fully replicate human diabetic cardiomyopathy. The in vitro human cell work used isolated cells rather than whole organ systems. No clinical data on CBD for diabetic heart disease was available.
Questions This Raises
- ?Would CBD show similar cardioprotective effects in type 2 diabetic cardiomyopathy?
- ?What doses would be needed in humans to achieve these effects?
Trust & Context
- Key Stat:
- CBD attenuated multiple pathological pathways in diabetic hearts simultaneously
- Evidence Grade:
- Preclinical study combining animal model and human cell data, with comprehensive mechanistic analysis but no clinical translation yet.
- Study Age:
- Published in 2010 in the Journal of the American College of Cardiology. Clinical research on CBD for cardiovascular conditions has continued.
- Original Title:
- Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
- Published In:
- Journal of the American College of Cardiology, 56(25), 2115-25 (2010)
- Authors:
- Rajesh, Mohanraj, Mukhopadhyay, Partha, Bátkai, Sándor, Patel, Vivek, Saito, Keita, Matsumoto, Shingo, Kashiwaya, Yoshihiro, Horváth, Béla, Mukhopadhyay, Bani, Becker, Lauren, Haskó, György, Liaudet, Lucas, Wink, David A, Veves, Aristidis, Mechoulam, Raphael, Pacher, Pál
- Database ID:
- RTHC-00444
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD help people with diabetic heart disease?
In mice and isolated human heart cells, CBD reduced multiple markers of heart damage from diabetes. However, these preclinical findings have not yet been tested in human clinical trials for diabetic cardiomyopathy.
How did CBD protect the heart?
CBD worked through multiple mechanisms: reducing inflammation (NF-kB, TNF-alpha), decreasing oxidative stress, preventing fibrosis (scarring), and reducing cell death in heart tissue.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-your-body-what-research-shows
- why-does-weed-make-eyes-red-blood-vessel
- why-does-weed-make-heart-race-cardiovascular
- thc-and-blood-pressure-medication-interactions
Cite This Study
https://rethinkthc.com/research/RTHC-00444APA
Rajesh, Mohanraj; Mukhopadhyay, Partha; Bátkai, Sándor; Patel, Vivek; Saito, Keita; Matsumoto, Shingo; Kashiwaya, Yoshihiro; Horváth, Béla; Mukhopadhyay, Bani; Becker, Lauren; Haskó, György; Liaudet, Lucas; Wink, David A; Veves, Aristidis; Mechoulam, Raphael; Pacher, Pál. (2010). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.. Journal of the American College of Cardiology, 56(25), 2115-25. https://doi.org/10.1016/j.jacc.2010.07.033
MLA
Rajesh, Mohanraj, et al. "Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.." Journal of the American College of Cardiology, 2010. https://doi.org/10.1016/j.jacc.2010.07.033
RethinkTHC
RethinkTHC Research Database. "Cannabidiol attenuates cardiac dysfunction, oxidative stress..." RTHC-00444. Retrieved from https://rethinkthc.com/research/rajesh-2010-cannabidiol-attenuates-cardiac-dysfunction
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.